Cargando…

Cost-effectiveness of adding rituximab to fludarabine and cyclophosphamide for treatment of chronic lymphocytic leukemia in Ukraine

The aim of this study was to assess the cost-effectiveness, from a health care perspective, of adding rituximab to fludarabine and cyclophosphamide scheme (FCR versus FC) for treatment-naïve and refractory/relapsed Ukrainian patients with chronic lymphocytic leukemia. A decision-analytic Markov coho...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mandrik, Olena, Corro Ramos, Isaac, Knies, Saskia, Al, Maiwenn, Severens, Johan L
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2015
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4555968/ https://www.ncbi.nlm.nih.gov/pubmed/26345331 http://dx.doi.org/10.2147/CMAR.S79258

Ejemplares similares

Economic value of in vitro fertilization in Ukraine, Belarus, and Kazakhstan
por: Mandrik, Olena, et al.
Publicado: (2015)

A phase II Japanese trial of fludarabine, cyclophosphamide and rituximab for previously untreated chronic lymphocytic leukemia
por: Izutsu, Koji, et al.
Publicado: (2020)

Cost comparison of treating chronic hepatitis C genotype one with pegylated interferons in Ukraine
por: Mandrik, Olena, et al.
Publicado: (2014)

Long-term survival in a patient with progressive multifocal leukoencephalopathy after therapy with rituximab, fludarabine and cyclophosphamide for chronic lymphocytic leukemia
por: Garrote, Heidys, et al.
Publicado: (2015)

Fludarabine-Cyclophosphamide-Rituximab Treatment in Chronic Lymphocytic Leukemia, Focusing on Long Term Cytopenias Before and After the Era of Targeted Therapies
por: Szász, Róbert, et al.
Publicado: (2021)

REVIEWING TRANSFERABILITY IN ECONOMIC EVALUATIONS ORIGINATING FROM EASTERN EUROPE
por: Mandrik, Olena, et al.
Publicado: (2015)

Rituximab and Fludarabine or Cyclophosphamide Combination Treatment for Older Waldenström Macroglobulinemia Patients
por: Xu, XiaoWei, et al.
Publicado: (2013)

A Case of Hemophagocytic Lymphohistiocytosis in a Patient with Chronic Lymphocytic Leukemia after Treatment with Fludarabine, Cyclophosphamide, and Rituximab Chemotherapy, with Autopsy Findings
por: Tiong, Ing S., et al.
Publicado: (2012)

Simultaneous clinical resolution of focal segmental glomerulosclerosis associated with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab
por: Arampatzis, Spyridon, et al.
Publicado: (2011)

Prognostic role of CD4 T-cell depletion after frontline fludarabine, cyclophosphamide and rituximab in chronic lymphocytic leukaemia
por: Gauthier, Martin, et al.
Publicado: (2019)

Analysis of Data on Fludarabine, Cyclophosphamide, and Rituximab Chemoimmunotherapy for Chronic Lymphocytic Leukemia Shows High Patient Heterogeneity and the Need for More Consideration of Individualized Treatment
por: Xu, Xiaoli, et al.
Publicado: (2022)

Cyclophosphamide/fludarabine/rituximab: Prolonged viral shedding and protracted COVID-19: case report
Publicado: (2022)

High prognostic value of measurable residual disease detection by flow cytometry in chronic lymphocytic leukemia patients treated with front-line fludarabine, cyclophosphamide, and rituximab, followed by three years of rituximab maintenance
por: García-Marco, José A., et al.
Publicado: (2019)

Prediction of poor outcome in CLL patients following first-line treatment with fludarabine, cyclophosphamide and rituximab
por: Fink, A M, et al.
Publicado: (2013)

Ibrutinib plus fludarabine, cyclophosphamide and rituximab (iFCR) as initial treatment in chronic lymphocytic leukemia/ small lymphocytic leukemia with or without TP53 aberrations: a prospective real-world study in Chinese cohort
por: Miao, Yi, et al.
Publicado: (2023)

Fludarabine in the treatment of chronic lymphocytic leukemia: a review
por: Ricci, Francesca, et al.
Publicado: (2009)

Development of fludarabine formulations in the treatment of chronic lymphocytic leukemia
por: Janssens, Ann, et al.
Publicado: (2009)

Obinutuzumab plus fludarabine and cyclophosphamide in previously untreated, fit patients with chronic lymphocytic leukemia: a subgroup analysis of the GREEN study
por: Bosch, Francesc, et al.
Publicado: (2019)

Impact of hypoglycemia on daily life of type 2 diabetes patients in Ukraine
por: Mandrik, Olena, et al.
Publicado: (2013)

T-cell large granular lymphocytic leukemia: treatment experience with fludarabine
por: Costa, Renata Oliveira, et al.
Publicado: (2012)

MicroRNAs involvement in fludarabine refractory chronic lymphocytic leukemia
por: Ferracin, Manuela, et al.
Publicado: (2010)

PB1878: CROSS-TRIAL ANALYSIS OF FIXED-DURATION IBRUTINIB (I) PLUS VENETOCLAX (V) VS FLUDARABINE (F), CYCLOPHOSPHAMIDE (C), AND RITUXIMAB (R) AS FIRST-LINE TREATMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
por: Barrientos, J. C., et al.
Publicado: (2022)

Aplastic Anemia Preconditioned with Fludarabine, Cyclophosphamide, and Anti-Thymocyte Globulin
por: Yang, Dan, et al.
Publicado: (2019)

Use of Value of Information in Healthcare Decision Making: Exploring Multiple Perspectives
por: Bindels, Jill, et al.
Publicado: (2015)

Do the Washington Panel recommendations hold for Europe: investigating the relation between quality of life versus work-status, absenteeism and presenteeism
por: Knies, Saskia, et al.
Publicado: (2014)

Alemtuzumab in the treatment of fludarabine refractory B-cell chronic lymphocytic leukemia (CLL)
por: Montillo, Marco, et al.
Publicado: (2008)

Fludarabine Treatment of Patient with Chronic Lymphocytic Leukemia Induces a Digital Ischemia
por: Soyaltin, Utku Erdem, et al.
Publicado: (2016)

Fludarabine-resistance associates with ceramide metabolism and leukemia stem cell development in chronic lymphocytic leukemia
por: Huang, Chunfa, et al.
Publicado: (2018)

Safety and Efficacy of Rituximab and Cyclophosphamide in a Case of Resistant Acquired Hemophilia A in Course of Chronic Lymphocytic Leukemia
por: Mazziotta, Francesco, et al.
Publicado: (2019)

Determination of genes and microRNAs involved in the resistance to fludarabine in vivo in chronic lymphocytic leukemia
por: Moussay, Etienne, et al.
Publicado: (2010)

Progressive multifocal leukoencephalopathy developing in a fludarabine naïve patient with chronic lymphocytic leukemia
por: Ooi, Melissa G, et al.
Publicado: (2009)

Integrating clinical and economic evidence in clinical guidelines: More needed than ever!
por: Knies, Saskia, et al.
Publicado: (2018)

The increasing importance of a continence nurse specialist to improve outcomes and save costs of urinary incontinence care: an analysis of future policy scenarios
por: Franken, Margreet G, et al.
Publicado: (2018)

Long term efficacy and safety of Fludarabine, Cyclophosphamide and Rituximab regimen followed by (90)Y-ibritumomab tiuxetan consolidation for the treatment of relapsed grades 1 and 2 follicular lymphoma
por: Pisani, Francesco, et al.
Publicado: (2015)

Matrix Metalloproteinase-9 Is Involved in Chronic Lymphocytic Leukemia Cell Response to Fludarabine and Arsenic Trioxide
por: Amigo-Jiménez, Irene, et al.
Publicado: (2014)

Fludarabine-based myeloablative regimen as pretransplant conditioning therapy in adult acute leukemia/myelodysplastic syndrome: comparison with oral or intravenous busulfan with cyclophosphamide
por: Lee, Ji Hyun, et al.
Publicado: (2010)

Beyond fludarabine: pentostatin plus cyclophosphamide are a well-tolerated alternative in reduced intensity conditioning
por: Dimitrova, Dimana, et al.
Publicado: (2022)

Bendamustine vs. fludarabine/cyclophosphamide lymphodepletion prior to BCMA CAR-T cell therapy in multiple myeloma
por: Sidana, Surbhi, et al.
Publicado: (2023)

Allogeneic stem cell transplant for multiple myeloma & myelofibrosis with split-dose busulfan, fludarabine & cyclophosphamide
por: Trunk, Andrew D., et al.
Publicado: (2023)

FCR (Fludarabine, Cyclophosphamide, Rituximab) regimen followed by (90)yttrium ibritumomab tiuxetan consolidation for the treatment of relapsed grades 1 and 2 follicular lymphoma: a report of 9 cases
por: Pisani, Francesco, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_ufdlge1bc0fsdi259qmemu6su7